Q32 Bio announces topline results from SIGNAL-AA Phase 2a Part B trial of bempikibart in alopecia areata

Q32 Bio Inc.

Topline results from 36-week Part B of SIGNAL-AA Phase 2a trial for bempikibart (ADX-914) in alopecia areata announced on July 13, 2026.
Presentation filed as Exhibit 99.1 contains detailed efficacy, safety, and biomarker data; no numerical results provided in the 8-K body.
Company cautions that additional data analyses may not support current beliefs; risks include trial costs, funding needs, and regulatory uncertainties.
Forward-looking statements highlight potential differences between topline and final results; stock may react to data in the exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.